uldn inverse titration protocol final

8/13/2019 ULDN Inverse Titration Protocol FINAL

1/50

Michael Robinson Nov 2013Page 1

UsingUltra Low Dose Naltrexoneto

reduce op iate use and trans i t ion to LDN.

A novel approach for patients withChronic Immune NeurologicalDiseases*to move away from

opiate use to manage symptomsof pain and fatigue.

* Chronic Immune Neurological Diseases of

"C.I.N.D. is a term that covers a wide range

of diseases affecting both the immune and

neurological systems. These include Lyme

disease, ME, CFS, CRPS, Fibromyalgia

(FMS) and MS.

Ultra-Low-Dose Opioid

Antagonists Enhance

Opioid Analgesia and

Reduce Tolerance

Lindsay H. Burns,Todd W.

Vanderah,Hoau-Yan Wang

12/2008; DOI:10.1007/978-1-59745-

197-0_1

ABSTRACT

Ultra-low-dose opioid

antagonists have been

shown to enhance opioid

analgesia and attenuate the

tolerance to analgesic

effects normally seen with

chronic opioid

administration.

Source

http://www.researchgate.net/publication/226837972

_Ultra-Low-

Dose_Opioid_Antagonists_Enhance_Opioid_Analg

esia_and_Reduce_Tolerance
http://www.researchgate.net/researcher/23505070_Lindsay_H_Burns/http://www.researchgate.net/researcher/15292617_Todd_W_Vanderah/http://www.researchgate.net/researcher/15292617_Todd_W_Vanderah/http://www.researchgate.net/researcher/14687245_Hoau-Yan_Wang/http://www.researchgate.net/publication/226837972_Ultra-Low-Dose_Opioid_Antagonists_Enhance_Opioid_Analgesia_and_Reduce_Tolerancehttp://www.researchgate.net/publication/226837972_Ultra-Low-Dose_Opioid_Antagonists_Enhance_Opioid_Analgesia_and_Reduce_Tolerancehttp://www.researchgate.net/publication/226837972_Ultra-Low-Dose_Opioid_Antagonists_Enhance_Opioid_Analgesia_and_Reduce_Tolerancehttp://www.researchgate.net/publication/226837972_Ultra-Low-Dose_Opioid_Antagonists_Enhance_Opioid_Analgesia_and_Reduce_Tolerancehttp://www.researchgate.net/publication/226837972_Ultra-Low-Dose_Opioid_Antagonists_Enhance_Opioid_Analgesia_and_Reduce_Tolerancehttp://www.researchgate.net/publication/226837972_Ultra-Low-Dose_Opioid_Antagonists_Enhance_Opioid_Analgesia_and_Reduce_Tolerancehttp://www.researchgate.net/publication/226837972_Ultra-Low-Dose_Opioid_Antagonists_Enhance_Opioid_Analgesia_and_Reduce_Tolerancehttp://www.researchgate.net/publication/226837972_Ultra-Low-Dose_Opioid_Antagonists_Enhance_Opioid_Analgesia_and_Reduce_Tolerancehttp://www.researchgate.net/publication/226837972_Ultra-Low-Dose_Opioid_Antagonists_Enhance_Opioid_Analgesia_and_Reduce_Tolerancehttp://www.researchgate.net/researcher/14687245_Hoau-Yan_Wang/http://www.researchgate.net/researcher/15292617_Todd_W_Vanderah/http://www.researchgate.net/researcher/15292617_Todd_W_Vanderah/http://www.researchgate.net/researcher/23505070_Lindsay_H_Burns/


2/50


AcknowledgementsThere are many people I need to acknowledge and thank for assisting with thecompilation of this information. I cannot thank them all but they all have one thing incommon. They advocate for their own health and they; advocate for the health andwell being of others; demanding better treatments against misinformation andapathy.

I also acknowledge the late Thomas Michael Hennessy, Jr. who passed away onSeptember 9, 2013 in Florida USA after 25 years of living with the debilitating symptomsof a Chronic Immune Neurological Disease. Thomas knew more than most about thepolitics and problems getting an accurate diagnostic definition as well as focusing themedical community on the multiple causes and effective treatments.see

Remembering Thomas Hennessy Jr. on Pg 50

DisclaimerThis information herein is not medical advice, it does not and should not replacemedical advice. It has been compiled and been made available in the hope thatpatients and medical professionals will become aware of the research and opinionsthat exists on the use and benefits of ULDN and LDN, the increasing use of ULDNand LDN.

Creative Commons Use / CCL Statement

Share and share alike ....

http://en.wikipedia.org/wiki/Share-alike
http://en.wikipedia.org/wiki/Share-alikehttp://en.wikipedia.org/wiki/Share-alikehttp://en.wikipedia.org/wiki/Share-alike


3/50


ContentsAcknowledgements ................................................................................................... 2

Disclaimer ................................................................................................................. 2

Creative Commons Use / CCL Statement ................................................................. 2

Open Letter ........................................................................................................... 5

Aims and benefits of the ULDN Approach: ................................................................ 6

Protocol Overview ..................................................................................................... 8

A novel role for agonists ...................................................................................... 12

Additional Reading .................................................................................................. 17

Treating the cause not just masking symptoms................................................ 18

ULDN .................................................................................................................. 20

Observations by Dr Boris Gimbarzevsky .......................................................... 20

A selection of studies and published works ...................................................... 21

Studied, Recommended, Prescribed & Advocated by... ................................... 29

LDN - Extract from article by Dr Mercola .......................................................... 34

Doses and dilutions for ULDN and LDN ........................................................... 37

A DIY guide to diluting a 50mg tablet for ULDN and LDN liquid. ...................... 38

An important note Re Fillers............................................................................. 40

An important note if you change methods or dispensing pharmacy.................. 40

Pharmacist Dr Skip Lenz comments ................................................................ 41

Improving your capacity for activity - What really does help? .................................. 42

Remembering Thomas Hennessy Jr. ...................................................................... 50


4/50


Clinical Success

ULDN reduces Opioid

Tolerance."

"....primary goals I had in using

Naltrexone in my patients was to

see if I could slow the rate of

development of opiate tolerance

in patients on chronic opiatetherapy...."

".... patients have been using

range from 10 micrograms to

100-200 micrograms 2-4 times

daily.

Dr Boris Gimarzevsky

Source and further information:

http://drgimbarzevsky.com/Naltrexone/Low_Dose_Naltrexone_Observations1.html
http://drgimbarzevsky.com/Naltrexone/Low_Dose_Naltrexone_Observations1.htmlhttp://drgimbarzevsky.com/Naltrexone/Low_Dose_Naltrexone_Observations1.htmlhttp://drgimbarzevsky.com/Naltrexone/Low_Dose_Naltrexone_Observations1.htmlhttp://drgimbarzevsky.com/Naltrexone/Low_Dose_Naltrexone_Observations1.htmlhttp://drgimbarzevsky.com/Naltrexone/Low_Dose_Naltrexone_Observations1.html


5/50


Open Letter

Friday 29th November 2013

To whom it may concern:

The following information introduces a safe and effective approach to supporting thereduction of opiate use for those patients with ME, CFS, FMS who due to post

exertion malaise have difficulty boosting the production of dopamine through

vigorous exercise.

With medical guidance and support the use of ULDN has been shown to:

- reduce opioid tolerance

- assist with the reduction of opioid medications use

With persistence and support to find the individually suitable doses the patient overtime seeks to move from using opioid medication to LDN.

The following information is a compilation of research, online articles and

discussions from doctors, researchers and patients. It is not intended to replace

medical advice but instead to raise awareness of the use of ultra low dose

naltrexone and low dose naltrexone as a safe, cheap and effective option.

References and sources are included as hyperlinks through the document not as

they would usually be references or tabled in an academic paper. This is document

is not intended to be an academic paper or replace professional medical advice butas a compilation of some of the information readily available.

Yours Sincerely

Michael D. Robinson

Sydney, NSW, Australia.

[email protected]

NOTE

ULDN and ULDTX have been used interchangeably in some online discussions.

ULDN = ULTRA Low Dose Naltrexone (ie micrograms usually between 10mcg and 200mcg)

LDN = Low Dose Naltrexone (ie mg usually between 0.5mg and 5mg)

For the purpose of simplicity and clarity for all readers 'mcg' has been used in this document for

'micrograms' instead of the usual ' g'.


6/50


Aims and benefits of the ULDN Approach:

The aim of this approach is to:

- reduce opiate tolerance;

- repair of the dopamine system affected by long term opiate medication;

- reduce opiate use

- taper opiate use to zero

- begin using LDN long term

ULDN assists both reducing opioid tolerance and also in chronic pain and auto

immune conditions like ME, Chronic Fatigue Syndrome and Fibromyalgia.

Studies and use of doses as small as nano and pico doses of Naltrexone have been

shown to also benefit. Studies and clinical experience of doctors and patients using

ULDN & LDN for this application show that there is a parabolic response to ultra low

doses. It is therefore more desirable for patients to be able to titrate the dose to find

the optimal dose.

Introducing ULDN assists the patient's recovery from the effects of long term opioid

use. As that recovery improves it may be possible to reduce opioid use with a goal

of tapering opioid use down, to zero use if possible.

Tailoring the treatment and inverse titration of opiate and ULDN medications allows

the patient to take the dose of each medication that maximises their progress

towards LDN use.

This "swap over" needs to be undertaken in a methodical, slow and steady manner

to first support the recovery of the dopamine receptors and production to support the

aim of moving towards replacing opiate use with LDN.

NOTE : This approach is in tended as part of an overal l comp rehensive

appro ach to regain ing health and wel l being.


7/50


See clinical review of evidence http://pain-topics.org/pdf/OpioidAntagonistsForPain.pdf

Clinical Success

More effective long term

treatment with LDN.

" (for)...... individuals suffering

from neuropathic pain, thisregime worked quite impressive

in our hands."

August 2010, Jan M. Keppel

Hesselink, MD, PhD

Source and further information:

http://www.neuropathie.nu/treatme

nt/low-dose-naltrexone-for-

neuropathic-pain.html
http://pain-topics.org/pdf/OpioidAntagonistsForPain.pdfhttp://pain-topics.org/pdf/OpioidAntagonistsForPain.pdfhttp://www.neuropathie.nu/treatment/low-dose-naltrexone-for-neuropathic-pain.htmlhttp://www.neuropathie.nu/treatment/low-dose-naltrexone-for-neuropathic-pain.htmlhttp://www.neuropathie.nu/treatment/low-dose-naltrexone-for-neuropathic-pain.htmlhttp://www.neuropathie.nu/treatment/low-dose-naltrexone-for-neuropathic-pain.htmlhttp://www.neuropathie.nu/treatment/low-dose-naltrexone-for-neuropathic-pain.htmlhttp://www.neuropathie.nu/treatment/low-dose-naltrexone-for-neuropathic-pain.htmlhttp://www.neuropathie.nu/treatment/low-dose-naltrexone-for-neuropathic-pain.htmlhttp://pain-topics.org/pdf/OpioidAntagonistsForPain.pdf


8/50


--- Opiate titration

----ULDN (ug / mcg) to LDN (mg) titration

Protocol Overview

Inverse titration of ULTRA LOW DOSE NALTREXONE and opioid medicationundertaken with physicians and patients working together is for the long term benefit of

the patient's well being. While some patients may find benefit in the first few weeks, itmay take other patients a few months to find a dose where the benefits of ULDN beginto be noticed.

The short acting immediate release ULDN is taken once daily around 10pm. This iswhen the body normally starts producing more dopamine and dopamine receptors.As ULDN only stays in the body for about 4 hours the "rebound" from even thesmallest short acting doses of ULDN causes the body produce more dopamine anddopamine receptors.

NOTE : The graphic below is an approximation for illustrative purposes only. It is not toscale and individual decisions should be made with medical advice consideringindividual situations.

1. Approx 3

months after

starting ULDN

begin slow

reduction of

opiates

2.After ULDNstarts to

support

dopamine then

reduce opioid

use, gradually

increasing

ULDN as able.

3. shows

gradual

increases of

ULDN doses

4. 14 days

after Opioid

zero use

taper ULDN

to LDN

5. gradual &

patient

increases to

LDN as

appropriate.


9/50


ULDN used in this way supports the repair of problems caused by long term opioidmedication use.

This problem is commonly referred to as " post opioid withdrawal syndrome".

Doctors commonly recommend patients re invigorate the dopamine system throughvigorous exercise but due to the complications such as "post exertion malaise", POTS orPostural Orthostatic Tachycardia Syndrome and Orthostatic Dysautonomia in patientswith ME/CFS/FMS, this type of exercise is not possible and causes serious worseningof their condition.

ULDN allows for a more controlled way to support recovery and reduce opioid usewithout the unnecessary complications of rapidly withdrawing opioid medications untilthe patient requires less medication. As the ULDN supports the "repair" of the patient'sdopamine receptors and production the opioid medication can be gradually reduced.

It should be kept in mind that patients that have persisting pain may struggle to achievethe goal of zero opioid use. LDN has been shown to reduce pain in patients howeverthe transition may be more challenging than both physician and patient hopes andrequire patience. . With patience and an experienced multi-disciplinary the aim is tocompletely swap the patient over from the ULDN + opiate mix and onto LDN as a longterm beneficial medication.

Although ULDN assists to repair the dopamine system it is a slow process and requirespatience the long term goal is to begin LDN without opiate use.

See also

http://pain-topics.org/pdf/OpioidAntagonistsForPain.pdfhttp://pain-topics.org/pdf/OpioidAntagonistsForPain.pdfhttp://pain-topics.org/pdf/OpioidAntagonistsForPain.pdf


10/50


ULDN dose requires individual titration

"The dose/ respon se cu rve of n al trexone po tent iat ion of analgesia appears to be

parabol ic; no response at too low a dose, a maximum response at a higher dose and then

decreasing effectiveness as one continues to increase naltrexone dose. At some point, the

dose of naltrexone will be high enough and it will be algesic; ie increase pain as it assumes

its expected opiate receptor blocking role. The dose of naltrexone that will antagonize

exogenous opiates and increase pain is quite variable among individuals. The lowest dose

I've seen put a chronic opiate user into withdrawal has been 1 mg; naltrexone is a

competative opiate antagonist and so to treat this withdrawal one needs to merely take more

opiates." Source:

http://drgimbarzevsky.com/Naltrexone/Low_Dose_Naltrexone_Observations1.html

see alsoObservations by Dr Boris Gimbarzevsky p20
http://drgimbarzevsky.com/Naltrexone/Low_Dose_Naltrexone_Observations1.htmlhttp://drgimbarzevsky.com/Naltrexone/Low_Dose_Naltrexone_Observations1.htmlhttp://drgimbarzevsky.com/Naltrexone/Low_Dose_Naltrexone_Observations1.html


11/50


Increases to ULDN dose should be made slowly and as a general guide variousdiscussions seem to indicate that after 3 or more months it will be much easier to

reduce opioid use reduced by 10% every 1 to 3 months.

This is a general guide for illustrative purposes only and individual approachesshould be guided by the ability of the patient to sustain a reduction in opioid use inconsultation with their treating doctors.

The longer the patient has been on opioid medications the more difficult it will be toreduce the dose. As a general guide it should be noted that the smaller the dosesbecome it may become harder to reduce opiate use however with ULDN thesedifficulties are lessened.

It should be kept in mind that the dopamine system being repaired has been alteredby the introduction of prescribed opioid medications taken long term and so and willtake time to repair. While all other multidisciplinary approaches to support thisprotocol should be encouraged it does need to be kept in mind that it will be aprocess that will happen at the patient's individual pace.

Patience and persistence will increase success as this may take many, and in factshould, be undertaken over months or even years rather than days or weeks.

After 10 - 14 days of no opioid use the dose of ULDN can be gradually increased to0.5mg (LDN levels for immune support) per day as either a single daily dose or splitdose and increased thereafter according to LDN protocols .

Ultra-low-dose opioid antagonists have been shown to enhance opioid

analgesia and attenuate the tolerance to analgesic effects normally

seen with chronic opioid administration. (Lindsay H. Burns,Todd W.Vanderah,Hoau-Yan Wang)

See: http://www.researchgate.net/publication/226837972_Ultra-Low-Dose_Opioid_Antagonists_Enhance_Opioid_Analgesia_and_Reduce_Tolerance .
http://www.researchgate.net/researcher/23505070_Lindsay_H_Burns/http://www.researchgate.net/researcher/23505070_Lindsay_H_Burns/http://www.researchgate.net/researcher/15292617_Todd_W_Vanderah/http://www.researchgate.net/researcher/15292617_Todd_W_Vanderah/http://www.researchgate.net/researcher/14687245_Hoau-Yan_Wang/http://www.researchgate.net/publication/226837972_Ultra-Low-Dose_Opioid_Antagonists_Enhance_Opioid_Analgesia_and_Reduce_Tolerancehttp://www.researchgate.net/publication/226837972_Ultra-Low-Dose_Opioid_Antagonists_Enhance_Opioid_Analgesia_and_Reduce_Tolerancehttp://www.researchgate.net/publication/226837972_Ultra-Low-Dose_Opioid_Antagonists_Enhance_Opioid_Analgesia_and_Reduce_Tolerancehttp://www.researchgate.net/publication/226837972_Ultra-Low-Dose_Opioid_Antagonists_Enhance_Opioid_Analgesia_and_Reduce_Tolerancehttp://www.researchgate.net/publication/226837972_Ultra-Low-Dose_Opioid_Antagonists_Enhance_Opioid_Analgesia_and_Reduce_Tolerancehttp://www.researchgate.net/researcher/14687245_Hoau-Yan_Wang/http://www.researchgate.net/researcher/15292617_Todd_W_Vanderah/http://www.researchgate.net/researcher/15292617_Todd_W_Vanderah/http://www.researchgate.net/researcher/23505070_Lindsay_H_Burns/


12/50


A novel role for agonists

Naloxone

Naltrexone and Naloxone (see p. 13) are commonly confused though have similar

pharmaceutical uses in some oral medications included for their anti injecting abuse

blockade role. Naloxone's two main uses are in anti injection abuse inclusion in

combination opioid medications with Naloxone combined and as a emergency

overdose reversal treatment.

See MIMS orhttp://en.wikipedia.org/wiki/Naloxonefor more information.

Some studies of the use of ultra low dose naloxone alone have been undertaken,

(mostly IV infusions) more common use of Naloxone is in combination medications

mentioned above such as Targin, Suboxone or Buprenorphine.


Targin (combination of Oxycontin and Naloxone) is often used by doctors for its

decreased opioid effect on the bowel but ULDN has a greater beneficial effect than

Naltrexone has. Other combined medications include Suboxone but these

combinations do not allow for individual titration of either Naloxone (similar to

naltrexone) or of the opiate dose.

In recent years the price of Naloxone has increased significatly internationally in

stark contrast to the low cost of Naltrexone.

Suboxone and Buprenorphine are both relatively new medications compared to

Naltrexone neither reduce tolerance and weaning of either medication is known to be

extremely difficult.

Current approx costs (in Australia) depending on dose for Targin, Suboxone or

Buprenorphine is around $ 1 .56 / day e.g. Buprenorphine

(oxycodone hydrochloride 20 mg + naloxone hydrochloride 10 mg tablet: modified release)

http://www.pbs.gov.au/medicine/item/8935G

though some options are significantly more expensive even on the PBS schedule.

Note the dose of Naloxone included in these medications is generally considered to

be for anti injection abuse purposes combination medications and has not been

extensively studied or used for the purposes of this protocol to support the dopamine

system, immune system and move the patient off opiates and onto LDN.
http://en.wikipedia.org/wiki/Naloxonehttp://en.wikipedia.org/wiki/Naloxonehttp://en.wikipedia.org/wiki/Naloxonehttp://pain-topics.org/pdf/OpioidAntagonistsForPain.pdfhttp://pain-topics.org/pdf/OpioidAntagonistsForPain.pdfhttp://www.pbs.gov.au/medicine/item/8935Ghttp://www.pbs.gov.au/medicine/item/8935Ghttp://www.pbs.gov.au/medicine/item/8935Ghttp://pain-topics.org/pdf/OpioidAntagonistsForPain.pdfhttp://en.wikipedia.org/wiki/Naloxone


13/50


Naltrexone 50mg extended release

Used at 50mg and 300mg doses Naltrexone is commonly as an opioid blockade medication

for heroin and alcohol addicts. At these doses is acts as an agonist to block opiates and

also reducing cravings for intoxicating substances.

Low Dose Naltrexone immediate releaseAt 0.025 to 5mg LDN has a beneficial effect on the immune and dopamine system.Immediate release LDN has a half life of 4 hours. LDN's role in this protocol is the repair ofthe opioid growth factor, dopamine and immune systems. At doses under 1mg has beenshown to not have a blockade effect that could precipitate withdrawals in patients usingopioid medications.

After patients have stopped using opiates for 14 days they can start on LDN. Generallystarting at 0.5mg and working up to 1.5mg and then even slower to around 4.5mg/ dayeither as a single or split dose. Where patients may need to take both LDN and painmedications more information is available on the LDN information sites regarding the use ofTramadol with LDN.

Dr Chris Steele, MBE, speaks about using LDN as a first choice as it effective, does no harmand is a safe drug. http://www.youtube.com/watch?v=CVpjsDK0LPA


Additional Reading

A e-book of resources and cases of LDN use for the First International LDN Awareness

Week 2009 by Julia Schopick see: http://preventionx.com/The-Faces-of-Low-Dose-

Naltrexone---HONEST-MEDICINE-My-Dream-for-download-w5661.html

Low dose naltrexone for neuropathic painhttp://www.neuropathie.nu/treatment/low-dose-naltrexone-for-neuropathic-pain.html

The Fibromyalgia drugs your doctor (probably) knows nothing about.

This article by Cort Johnsonhttp://www.cortjohnson.org/ one of the leading advocates forCFS and Fibromyalgia research, awareness and improved treatments explains this opioidantagonist .. .. "Opio id AntagonistsMore extensive use of opioid antagonists as well as the introduction of novel microglial activation

inhibitors (miRNA) pose exciting new possibilities for the treatment of FMS.Ablin and Buskila

It may seem strange to target drugs that knock down one of the main pain inhibitingsystems in the body but the opioid receptors in many FM patients appear to filled andelevated opioid activity in the brain can cause increased, not decreased pain sensitivity.

Low Dose Naltrexone (LDN)An opioid antagonist long used by people with fibromyalgiafor relief, LDN finally got a clinical trial and it was successful. At the low doses used in thetrial, Ablin and Busklin suggested LDNs effectiveness in FM may have been more due toanti-inflammatory effects than to opioid antagonism....."

seehttp://www.prohealth.com/library/showarticle.cfm?libid=18225

see also http://ldninfo.org/others.htm

http://www.bwmbagus.demon.co.uk/BobsDocs/0-LDN-Side-effects.pdf
http://www.youtube.com/watch?v=CVpjsDK0LPAhttp://www.youtube.com/watch?v=CVpjsDK0LPAhttp://pain-topics.org/pdf/OpioidAntagonistsForPain.pdfhttp://pain-topics.org/pdf/OpioidAntagonistsForPain.pdfhttp://preventionx.com/The-Faces-of-Low-Dose-Naltrexone---HONEST-MEDICINE-My-Dream-for-download-w5661.htmlhttp://preventionx.com/The-Faces-of-Low-Dose-Naltrexone---HONEST-MEDICINE-My-Dream-for-download-w5661.htmlhttp://preventionx.com/The-Faces-of-Low-Dose-Naltrexone---HONEST-MEDICINE-My-Dream-for-download-w5661.htmlhttp://www.neuropathie.nu/treatment/low-dose-naltrexone-for-neuropathic-pain.htmlhttp://www.neuropathie.nu/treatment/low-dose-naltrexone-for-neuropathic-pain.htmlhttp://www.cortjohnson.org/http://www.cortjohnson.org/http://www.cortjohnson.org/http://www.prohealth.com/library/showarticle.cfm?libid=18225http://www.prohealth.com/library/showarticle.cfm?libid=18225http://www.prohealth.com/library/showarticle.cfm?libid=18225http://ldninfo.org/others.htmhttp://ldninfo.org/others.htmhttp://www.bwmbagus.demon.co.uk/BobsDocs/0-LDN-Side-effects.pdfhttp://www.bwmbagus.demon.co.uk/BobsDocs/0-LDN-Side-effects.pdfhttp://www.bwmbagus.demon.co.uk/BobsDocs/0-LDN-Side-effects.pdfhttp://ldninfo.org/others.htmhttp://www.prohealth.com/library/showarticle.cfm?libid=18225http://www.cortjohnson.org/http://www.neuropathie.nu/treatment/low-dose-naltrexone-for-neuropathic-pain.htmlhttp://preventionx.com/The-Faces-of-Low-Dose-Naltrexone---HONEST-MEDICINE-My-Dream-for-download-w5661.htmlhttp://preventionx.com/The-Faces-of-Low-Dose-Naltrexone---HONEST-MEDICINE-My-Dream-for-download-w5661.htmlhttp://pain-topics.org/pdf/OpioidAntagonistsForPain.pdfhttp://www.youtube.com/watch?v=CVpjsDK0LPA


14/50


Ultra Low Dose Naltrexone immediate release

ULDN (1microgram - 500micrograms)

Even at pico, nano and ultra low doses naltrexone has beneficial effects on the

immune and dopamine systems. The dose requires titration for individual patients as

at these low doses the beneficial dose can be parabolic and requires individualtitration to find the dose that best suits. As patients improve the dose can be

increased accordingly.

It is important that in prescribing and dispensing ULDN fillers used in tablets and

capsules not interfere with the immediate release. An experienced LDN

compounding pharmacy be used or a suitable 50mg tablet be dissolved in distilled

water by the patient and the appropriate liquid dose be measured.

ULDN has been studied and shown to:

- prevent injection abuse (like Naloxone) in oral medications without affecting theopioid effect.- reduce opioid tolerance,- improves immune support function.- is not sufficiently large enough dose to cause blockade (ie does not causewithdrawals)

Current approximate costs of LDN and ULDN in Australia

For Australian purposes and using one 50mg Naltrexone tablet per month diluted in

distilled water to measure out liquid dose of LDN or ULDN the cost is approx 9c /day.

ie $136 for 30 x 50mg tablets

= $2.72 per month

= 9 cents per day

Source:

http://www.pbs.gov.au/medicine/item/8370M

" (for)...... individuals suffering from neuropathic pain, this regimeworked quite impressive in our hands."

August 2010, Jan M. Keppel Hesselink, MD, PhD

http://www.neuropathie.nu/treatment/low-dose-naltrexone-for-neuropathic-pain.html
http://www.pbs.gov.au/medicine/item/8370Mhttp://www.pbs.gov.au/medicine/item/8370Mhttp://www.neuropathie.nu/treatment/low-dose-naltrexone-for-neuropathic-pain.htmlhttp://www.neuropathie.nu/treatment/low-dose-naltrexone-for-neuropathic-pain.htmlhttp://www.neuropathie.nu/treatment/low-dose-naltrexone-for-neuropathic-pain.htmlhttp://www.pbs.gov.au/medicine/item/8370M


15/50


Opioid Antagonists in Pain Management

Available evidence suggests that the

opioid antagonists naloxone and

naltrexone offer potential benefits for

enhancing opioid analgesia as well as

monotherapy for managing certain

challenging pain conditions.

By Stewart B. Leavitt, MA, PhD

ULDN science published studies

http://www.science.gov/topicpages/u/ultra-low+dose+naltrexone.html
http://www.science.gov/topicpages/u/ultra-low+dose+naltrexone.htmlhttp://www.science.gov/topicpages/u/ultra-low+dose+naltrexone.htmlhttp://www.science.gov/topicpages/u/ultra-low+dose+naltrexone.htmlhttp://www.science.gov/topicpages/u/ultra-low+dose+naltrexone.html


16/50


17/50


ULDN and LDN Naltrexone offers many benefits over Naloxone - as

Naltrexone benefits neuropathic pain conditions, "rests" the opioid

receptor system, enhancing analgesia while overcoming prior

opioid tolerance or hyperanalgesia.

SeeError! Reference source not found.http://preventionx.com/download.php?id=5675

Additional Reading


Standford Researchers get to the root of stopping the pain rather thanmasking it .

http://alumni.stanford.edu/get/page/magazine/article/?article_id=66226

....."In a 2013 study by Younger's team, 31fibromyalgiapatients treated with low

doses of a drug called Naltrexonethat inhibits microglial cells in the CNS reported

significantly less daily painon average compared with a placebo pill.

The link between the immune system and chronic pain is an unfolding story that

encompasses other types of chronic pain, including complex regional pain

syndrome.David Clark, a professor of anesthesia who studies the condition, notesthat some of its features" .... "the development of neurological problemsare

reminiscent of autoimmune disorders." *

* (i.e. ULDN and LDN helps the improvement of such autoimmune disorders)

For more information on this study see

http://updates.pain-topics.org/2012/03/low-dose-naltrexone-eases-fibromyalgia.html
http://preventionx.com/download.php?id=5675http://preventionx.com/download.php?id=5675http://pain-topics.org/pdf/OpioidAntagonistsForPain.pdfhttp://pain-topics.org/pdf/OpioidAntagonistsForPain.pdfhttp://alumni.stanford.edu/get/page/magazine/article/?article_id=66226http://alumni.stanford.edu/get/page/magazine/article/?article_id=66226http://updates.pain-topics.org/2012/03/low-dose-naltrexone-eases-fibromyalgia.htmlhttp://updates.pain-topics.org/2012/03/low-dose-naltrexone-eases-fibromyalgia.htmlhttp://updates.pain-topics.org/2012/03/low-dose-naltrexone-eases-fibromyalgia.htmlhttp://alumni.stanford.edu/get/page/magazine/article/?article_id=66226http://pain-topics.org/pdf/OpioidAntagonistsForPain.pdfhttp://preventionx.com/download.php?id=5675


18/50


The Journal of PainVolume 9, Issue 8, Pages 700-713,August 2008

Oxycodone Plus Ultra-Low-Dose

Naltrexone Attenuates Neuropathic

Pain and Associated -Opioid

ReceptorGsCoupling

Tally M. Largent-Milnes,Wenhong Guo, Hoau-Yan Wang,Lindsay H. BurnsToddW. Vanderah

Treating the cause not just masking symptoms

A presentation about the history and need for improvements to treating chronic pain.http://www.janussc.org/downloads/Opioids_and_Post_Op_Pain_Management.pdf

There are many other links and attachments referred to throughout the rest of thisdocument that address ULDN more specifically however it is prudent to put thisdiscussion in context. Throughout this document are references to the need to improvetreatment of Chronic Pain. This presentation explains the importance of a newapproach.

Traditionally anyone with chronic pain has been prescribed pain masking medication,the long term use of which does not improve their chronic pain nor their health.

For those with chronic immune neurological diseases including Lyme, ME, CFS andFibromyalgia as too often when their treating doctors have not had a test result to point

to as a cause of the pain start to blame the patient and suggest the pain is imaginary.

Thankfully as more studies give more doctors information they can understand aboutwhat the disease is doing to their patient they can better provide treatments morespecific to the causes rather than simply guessing at treatments and prescribingsymptom masking pain medications.

Pages 1 - 15 of the document outlines historical use of opioids. This information iscovered in many places but for the purposes of this document it is at least worthmentioning in passing.http://www.janussc.org/downloads/Opioids_and_Post_Op_Pain_Management.pdf

The historical context explains the history of theold approach for chronic pain conditions includingFibromyalgia. (Note there is extensive publishedmaterial about the difficulties of treatingFibromyalgia, tolerance and poor response toopioids as well as the need to consider Lyme,mold and other causes in order to address thecause rather than simply make the condition worseby exacerbating a chronic pain condition with longterm opioid use problems. These include effects

on hormones, the dopamine system as well ashyper analgesia.)

In this regard the chart on page 15of

http://www.janussc.org/downloads/Opioids_and_Post_Op_Pain_Management.pdf

also discusses Magnesium use to reduce pain. Addressing the issue of supplements(including magnesium and Vitamin D3 as well as tailoring dietary approaches toeliminate food intolerances and addressing issues as far ranging as muscle and jointinjuries to viral, mold and chemical exposure are also necessary).
http://www.jpain.org/issues?issue_key=S1526-5900(08)X0008-2http://www.jpain.org/issues?issue_key=S1526-5900(08)X0008-2http://www.jpain.org/article/S1526-5900(08)00480-X/abstracthttp://www.jpain.org/article/S1526-5900(08)00480-X/abstracthttp://www.jpain.org/article/S1526-5900(08)00480-X/abstracthttp://www.jpain.org/article/S1526-5900(08)00480-X/abstracthttp://www.jpain.org/article/S1526-5900(08)00480-X/abstracthttp://www.jpain.org/article/S1526-5900(08)00480-X/abstracthttp://www.jpain.org/article/S1526-5900(08)00480-X/abstracthttp://www.jpain.org/article/S1526-5900(08)00480-X/abstracthttp://www.jpain.org/article/S1526-5900(08)00480-X/abstracthttp://www.jpain.org/article/S1526-5900(08)00480-X/abstracthttp://www.janussc.org/downloads/Opioids_and_Post_Op_Pain_Management.pdfhttp://www.janussc.org/downloads/Opioids_and_Post_Op_Pain_Management.pdfhttp://www.janussc.org/downloads/Opioids_and_Post_Op_Pain_Management.pdfhttp://www.janussc.org/downloads/Opioids_and_Post_Op_Pain_Management.pdfhttp://www.janussc.org/downloads/Opioids_and_Post_Op_Pain_Management.pdfhttp://www.janussc.org/downloads/Opioids_and_Post_Op_Pain_Management.pdfhttp://www.janussc.org/downloads/Opioids_and_Post_Op_Pain_Management.pdfhttp://www.janussc.org/downloads/Opioids_and_Post_Op_Pain_Management.pdfhttp://www.janussc.org/downloads/Opioids_and_Post_Op_Pain_Management.pdfmailto:[email protected]://www.jpain.org/article/S1526-5900(08)00480-X/abstracthttp://www.jpain.org/article/S1526-5900(08)00480-X/abstracthttp://www.jpain.org/article/S1526-5900(08)00480-X/abstracthttp://www.jpain.org/article/S1526-5900(08)00480-X/abstracthttp://www.jpain.org/article/S1526-5900(08)00480-X/abstracthttp://www.jpain.org/article/S1526-5900(08)00480-X/abstracthttp://www.jpain.org/article/S1526-5900(08)00480-X/abstracthttp://www.jpain.org/article/S1526-5900(08)00480-X/abstracthttp://www.jpain.org/article/S1526-5900(08)00480-X/abstracthttp://www.jpain.org/article/S1526-5900(08)00480-X/abstracthttp://www.jpain.org/article/S1526-5900(08)00480-X/abstracthttp://www.jpain.org/article/S1526-5900(08)00480-X/abstracthttp://www.jpain.org/issues?issue_key=S1526-5900(08)X0008-2


19/50


20/50


ULDN

Observations by Dr Boris Gimbarzevsky

Selected extracts

".... Even though the doses of naltrexone may seem miniscule, there are some veryinteresting things that seem to happen with endogenous opiate systems when oneuses naltrexone in conjunction with opiates.

Dr. Boris Gimbarzevsky 20/4/2004

Source:http://drgimbarzevsky.com/Naltrexone/Low_Dose_Naltrexone_Observations1.html

"...One of the primary goals .... slow the rate of development of opiate tolerance inpatients on chronic opiate therapy."



"....If the result was due to placebo effect, then one would expect pain relief at the 1microgram dose. This dose did absolutely nothing for her and once she hit 10micrograms good analgesia resulted. Now the placebo effect is thought to bemediated by endorphins as placebo analgesia can be blocked with intravenous

naloxone and it could be that my action of giving her the naltrexone resulted inincreased endorphin release and the ULDNTX potentiated these endorphin effects.She continued to use the naltrexone with good ..."



Generally I suggest to patients that they experiment with combining microgramdoses of naltrexone with opiate analgesics and I have seen reductions ...... in opiate

analgesic doses when this approach has been used. One indication that a drug isdoing something is when patients ask for more of it. I've had patients use opiatesand naltrexone in combination and then come back asking for more naltrexone as itseemed to be helping with analgesia.



More at http://drgimbarzevsky.com/Naltrexone/Low_Dose_Naltrexone_Observations1.htmlandhttp://drgimbarzevsky.com/Naltrexone/
http://drgimbarzevsky.com/Naltrexone/Low_Dose_Naltrexone_Observations1.htmlhttp://drgimbarzevsky.com/Naltrexone/Low_Dose_Naltrexone_Observations1.htmlhttp://drgimbarzevsky.com/Naltrexone/Low_Dose_Naltrexone_Observations1.htmlhttp://drgimbarzevsky.com/Naltrexone/Low_Dose_Naltrexone_Observations1.htmlhttp://drgimbarzevsky.com/Naltrexone/Low_Dose_Naltrexone_Observations1.htmlhttp://drgimbarzevsky.com/Naltrexone/Low_Dose_Naltrexone_Observations1.htmlhttp://drgimbarzevsky.com/Naltrexone/Low_Dose_Naltrexone_Observations1.htmlhttp://drgimbarzevsky.com/Naltrexone/Low_Dose_Naltrexone_Observations1.htmlhttp://drgimbarzevsky.com/Naltrexone/Low_Dose_Naltrexone_Observations1.htmlhttp://drgimbarzevsky.com/Naltrexone/Low_Dose_Naltrexone_Observations1.htmlhttp://drgimbarzevsky.com/Naltrexone/http://drgimbarzevsky.com/Naltrexone/http://drgimbarzevsky.com/Naltrexone/http://drgimbarzevsky.com/Naltrexone/http://drgimbarzevsky.com/Naltrexone/Low_Dose_Naltrexone_Observations1.htmlhttp://drgimbarzevsky.com/Naltrexone/Low_Dose_Naltrexone_Observations1.htmlhttp://drgimbarzevsky.com/Naltrexone/Low_Dose_Naltrexone_Observations1.htmlhttp://drgimbarzevsky.com/Naltrexone/Low_Dose_Naltrexone_Observations1.htmlhttp://drgimbarzevsky.com/Naltrexone/Low_Dose_Naltrexone_Observations1.html


21/50


A selection of studies and published works


The following few pages are just a selection of the published studies listed on

Sciece.gov into the use of Ultra Low Dose Naltrexone

For more see http://ldninfo.org/ldn_trials.htm


Ultra-low-dosenaltrexonereduces the rewarding potency ofoxycodone and relapse vulnerability in ratsMicrosoft Academic SearchUltra-low-doseopioid antagonists have been shown to enhance opioid analgesia and

alleviate opioid tolerance and dependence. ............ potential of oxycodone+ultra-low-dosenaltrexone(NTX) versus oxycodone alone. ..........Francesco Leri; Lindsay H. Burns2005-01-01


Human abuse liability assessment of oxycodone combined with ultra-low-dosenaltrexoneMicrosoft Academic Search

......" Preclinical and clinical studies have shown that opioids combined withultra-low-dosenaltrexone(NTX) may have increased\\u000a analgesic potency and have

suggested reduced abuse or dependence liability. ....."David Andrew Tompkins; Ryan K. Lanier; Joseph A. Harrison; Eric C. Strain; George E.Bigelow

2010-01-01


Ultra-low-dosenaltrexonesuppresses rewarding effects of opiatesand aversive effects of opiate withdrawal in rats

Microsoft Academic SearchRationale Ultra-low-doseopioid antagonists enhance opiate analgesia and attenuatetolerance and withdrawal........ Objectives To determine whether ultra-low-

dosenaltrexone(NTX) coadministration alters the rewarding effects of opiates or the

aversive\\u000a effects of opiate withdrawal.\\u000a \\u000a \\u000a \\u000a

Methods We used the conditioned place preference (CPP) and conditioned place

aversion (CPA) paradigms to assess whether ultra-low-dose\\u000a NTX alters the

acute rewarding effects of oxycodone or morphine, or theMary C. Olmstead; Lindsay H. Burns2005-01-01

http://pain-topics.org/pdf/OpioidAntagonistsForPain.pdfhttp://pain-topics.org/pdf/OpioidAntagonistsForPain.pdfhttp://ldninfo.org/ldn_trials.htmhttp://ldninfo.org/ldn_trials.htmhttp://ldninfo.org/ldn_trials.htmhttp://www.science.gov/topicpages/u/ultra-low+dose+naltrexone.htmlhttp://www.science.gov/topicpages/u/ultra-low+dose+naltrexone.htmlhttp://science.gov/scigov/link.html?type=RESULT&redirectUrl=http://www.paintherapeutics.com/publications/Leri_2005.pdfhttp://science.gov/scigov/link.html?type=RESULT&redirectUrl=http://www.paintherapeutics.com/publications/Leri_2005.pdfhttp://science.gov/scigov/link.html?type=RESULT&redirectUrl=http://www.paintherapeutics.com/publications/Leri_2005.pdfhttp://science.gov/scigov/link.html?type=RESULT&redirectUrl=http://www.paintherapeutics.com/publications/Leri_2005.pdfhttp://science.gov/scigov/link.html?type=RESULT&redirectUrl=http://www.paintherapeutics.com/publications/Leri_2005.pdfhttp://science.gov/scigov/link.html?type=RESULT&redirectUrl=http://www.paintherapeutics.com/publications/Leri_2005.pdfhttp://academic.research.microsoft.com/http://academic.research.microsoft.com/http://www.science.gov/topicpages/u/ultra-low+dose+naltrexone.htmlhttp://www.science.gov/topicpages/u/ultra-low+dose+naltrexone.htmlhttp://science.gov/scigov/link.html?type=RESULT&redirectUrl=http://www.springerlink.com/index/uq763g1v869466p6.pdfhttp://science.gov/scigov/link.html?type=RESULT&redirectUrl=http://www.springerlink.com/index/uq763g1v869466p6.pdfhttp://science.gov/scigov/link.html?type=RESULT&redirectUrl=http://www.springerlink.com/index/uq763g1v869466p6.pdfhttp://science.gov/scigov/link.html?type=RESULT&redirectUrl=http://www.springerlink.com/index/uq763g1v869466p6.pdfhttp://academic.research.microsoft.com/http://academic.research.microsoft.com/http://www.science.gov/topicpages/u/ultra-low+dose+naltrexone.htmlhttp://www.science.gov/topicpages/u/ultra-low+dose+naltrexone.htmlhttp://science.gov/scigov/link.html?type=RESULT&redirectUrl=http://www.springerlink.com/index/m22348m5v6up5779.pdfhttp://science.gov/scigov/link.html?type=RESULT&redirectUrl=http://www.springerlink.com/index/m22348m5v6up5779.pdfhttp://science.gov/scigov/link.html?type=RESULT&redirectUrl=http://www.springerlink.com/index/m22348m5v6up5779.pdfhttp://science.gov/scigov/link.html?type=RESULT&redirectUrl=http://www.springerlink.com/index/m22348m5v6up5779.pdfhttp://science.gov/scigov/link.html?type=RESULT&redirectUrl=http://www.springerlink.com/index/m22348m5v6up5779.pdfhttp://science.gov/scigov/link.html?type=RESULT&redirectUrl=http://www.springerlink.com/index/m22348m5v6up5779.pdfhttp://academic.research.microsoft.com/http://academic.research.microsoft.com/http://www.science.gov/topicpages/u/ultra-low+dose+naltrexone.htmlhttp://www.science.gov/topicpages/u/ultra-low+dose+naltrexone.htmlhttp://www.science.gov/topicpages/u/ultra-low+dose+naltrexone.htmlhttp://academic.research.microsoft.com/http://science.gov/scigov/link.html?type=RESULT&redirectUrl=http://www.springerlink.com/index/m22348m5v6up5779.pdfhttp://science.gov/scigov/link.html?type=RESULT&redirectUrl=http://www.springerlink.com/index/m22348m5v6up5779.pdfhttp://www.science.gov/topicpages/u/ultra-low+dose+naltrexone.htmlhttp://academic.research.microsoft.com/http://science.gov/scigov/link.html?type=RESULT&redirectUrl=http://www.springerlink.com/index/uq763g1v869466p6.pdfhttp://science.gov/scigov/link.html?type=RESULT&redirectUrl=http://www.springerlink.com/index/uq763g1v869466p6.pdfhttp://www.science.gov/topicpages/u/ultra-low+dose+naltrexone.htmlhttp://academic.research.microsoft.com/http://science.gov/scigov/link.html?type=RESULT&redirectUrl=http://www.paintherapeutics.com/publications/Leri_2005.pdfhttp://science.gov/scigov/link.html?type=RESULT&redirectUrl=http://www.paintherapeutics.com/publications/Leri_2005.pdfhttp://www.science.gov/topicpages/u/ultra-low+dose+naltrexone.htmlhttp://ldninfo.org/ldn_trials.htmhttp://pain-topics.org/pdf/OpioidAntagonistsForPain.pdf


22/50


Oxycodone Plus Ultra-Low-DoseNaltrexoneAttenuates NeuropathicPain and Associated ?-Opioid ReceptorG s CouplingMicrosoft Academic SearchBoth peripheral nerve injury and chronic opioid treatment can result in hyperalgesia

associated with enhanced excitatory neurotransmission at the level of the spinal cord.

Chronic opioid administration leads to a shift in ?-opioid receptor (MOR)G protein

coupling from Gi\\/o to Gs that can be prevented by cotreatment with an ultra-low-

doseopioid antagonist. In this study, using lumbar spinal cord tissueTally M. Largent-Milnes; Wenhong Guo; Hoau-Yan Wang; Lindsay H. Burns; Todd W.Vanderah2008-01-01


http://www.jpain.org/article/S1526-5900(08)00480-X/abstract

Enhancing acupuncture by low dosenaltrexone.PubMedTo find appropriate and effective treatment options for chronic pain syndromes is a

challenging task. Multimodal treatment approach has been gaining acceptance for

chronic pain. However, combining treatments, such as acupuncture, with rationalpharmacology is still in its infancy. Acupuncture influences the opioid and cannabinoid

system through releasing endogenous receptor ligands. Low dosenaltrexonealso acts

on both these systems, and upregulates the opioid and cannabinoid receptors. The

authors hypothesise that low dosenaltrexonecould enhance the pain-relieving effect of

acupuncture. PMID:21415049Hesselink, Jan M Keppel; Kopsky, David J2011-03-17

http://science.gov/scigov/link.html?type=RESULT&redirectUrl=http://academic.research.microsoft.com/Publication/30329298http://science.gov/scigov/link.html?type=RESULT&redirectUrl=http://academic.research.microsoft.com/Publication/30329298http://science.gov/scigov/link.html?type=RESULT&redirectUrl=http://academic.research.microsoft.com/Publication/30329298http://science.gov/scigov/link.html?type=RESULT&redirectUrl=http://academic.research.microsoft.com/Publication/30329298http://science.gov/scigov/link.html?type=RESULT&redirectUrl=http://academic.research.microsoft.com/Publication/30329298http://science.gov/scigov/link.html?type=RESULT&redirectUrl=http://academic.research.microsoft.com/Publication/30329298http://science.gov/scigov/link.html?type=RESULT&redirectUrl=http://academic.research.microsoft.com/Publication/30329298http://academic.research.microsoft.com/http://academic.research.microsoft.com/http://www.science.gov/topicpages/u/ultra-low+dose+naltrexone.htmlhttp://www.science.gov/topicpages/u/ultra-low+dose+naltrexone.htmlhttp://www.jpain.org/article/S1526-5900(08)00480-X/abstracthttp://www.jpain.org/article/S1526-5900(08)00480-X/abstracthttp://science.gov/scigov/link.html?type=RESULT&redirectUrl=http://www.ncbi.nlm.nih.gov/pubmed/21415049http://science.gov/scigov/link.html?type=RESULT&redirectUrl=http://www.ncbi.nlm.nih.gov/pubmed/21415049http://science.gov/scigov/link.html?type=RESULT&redirectUrl=http://www.ncbi.nlm.nih.gov/pubmed/21415049http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmedhttp://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmedhttp://www.science.gov/topicpages/u/ultra-low+dose+naltrexone.htmlhttp://www.science.gov/topicpages/u/ultra-low+dose+naltrexone.htmlhttp://www.science.gov/topicpages/u/ultra-low+dose+naltrexone.htmlhttp://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmedhttp://science.gov/scigov/link.html?type=RESULT&redirectUrl=http://www.ncbi.nlm.nih.gov/pubmed/21415049http://www.jpain.org/article/S1526-5900(08)00480-X/abstracthttp://www.science.gov/topicpages/u/ultra-low+dose+naltrexone.htmlhttp://academic.research.microsoft.com/http://science.gov/scigov/link.html?type=RESULT&redirectUrl=http://academic.research.microsoft.com/Publication/30329298http://science.gov/scigov/link.html?type=RESULT&redirectUrl=http://academic.research.microsoft.com/Publication/30329298


23/50


24/50


Recent Patents on CNS Drug Discovery, 2010, 5, 210-220

PTI-609: A Novel Analgesic that Binds Filamin A to Control OpioidSignalingLindsay H. Burns,and Hoau-Yan Wang

Pain Therapeutics Inc., San Mateo, CA,Dept. of Pharmacology and Physiology, CUNY Medical School, New York,NY, USAReceived: June 4, 2010; Accepted: August 9, 2010; Revised: August 13, 2010

http://www.paintrials.com/publications/pti609_JournalArticle.pdf

Opiate Receptors and Antagonists: From Bench to Clinic

edited by Reginald L. Dean, Edward J. Bilsky, S. Stevens Negus

source

http://books.google.com.au/books?id=zqj2vy6VFUcC&pg=PA9&lpg=PA9&dq=Opioid%22ultra+low+dose+naltrexone%22&sour

ce=bl&ots=z2opO-

l_e2&sig=7WkwQykEY5uH15J6cSrftqDcxZY&hl=en&sa=X&ei=Wm2PUvzZIq3xiAfsoYDACw&ved=0CHIQ6AEwCA#v=onepag

e&q=Opioid%22ultra%20low%20dose%20naltrexone%22&f=false

see p 9 for more information about the benefits of the combination of opioids with

ULDN

For more scholarly discussion of the workings of Naltrexone seeAntidotes: Advances in Research and Application: 2011 Edition: Scholarly

Brief

Ch 2 pp 28...

http://books.google.com.au/books?id=JG64gRbV3DYC&pg=PA28&lpg=PA28&dq=:+A+Novel+Analgesic+that+Binds+Filamin+A+to+Control+Opioid+Signaling&source=bl&ots=5Vj2XBc6s3&sig=DNyQxUHFauxDTtD6F1lApullUGM&hl=en&sa=X&ei=0qCfUueNNeayiQfe2ID4DA&ved=0CEoQ6AEwAw#v=onepage&q=%3A%20A%20Novel%20Analgesic%20that%20Binds%20Filamin%20A%20to%20Control%20Opioid%20Signaling&f=false

..." Combined with opiates, ultra-low-dose naloxone or naltrexone can

enhance and prolong the analgesia of the opiate alone and prevent or

attenuate opioid ..."
http://www.paintrials.com/publications/pti609_JournalArticle.pdfhttp://www.paintrials.com/publications/pti609_JournalArticle.pdfhttp://books.google.com.au/books?id=zqj2vy6VFUcC&pg=PA9&lpg=PA9&dq=Opioid%22ultra+low+dose+naltrexone%22&source=bl&ots=z2opO-l_e2&sig=7WkwQykEY5uH15J6cSrftqDcxZY&hl=en&sa=X&ei=Wm2PUvzZIq3xiAfsoYDACw&ved=0CHIQ6AEwCA#v=onepage&q=Opioid%22ultra%20low%20dose%20naltrexone%22&f=falsehttp://books.google.com.au/books?id=zqj2vy6VFUcC&pg=PA9&lpg=PA9&dq=Opioid%22ultra+low+dose+naltrexone%22&source=bl&ots=z2opO-l_e2&sig=7WkwQykEY5uH15J6cSrftqDcxZY&hl=en&sa=X&ei=Wm2PUvzZIq3xiAfsoYDACw&ved=0CHIQ6AEwCA#v=onepage&q=Opioid%22ultra%20low%20dose%20naltrexone%22&f=falsehttp://books.google.com.au/books?id=zqj2vy6VFUcC&pg=PA9&lpg=PA9&dq=Opioid%22ultra+low+dose+naltrexone%22&source=bl&ots=z2opO-l_e2&sig=7WkwQykEY5uH15J6cSrftqDcxZY&hl=en&sa=X&ei=Wm2PUvzZIq3xiAfsoYDACw&ved=0CHIQ6AEwCA#v=onepage&q=Opioid%22ultra%20low%20dose%20naltrexone%22&f=falsehttp://books.google.com.au/books?id=zqj2vy6VFUcC&pg=PA9&lpg=PA9&dq=Opioid%22ultra+low+dose+naltrexone%22&source=bl&ots=z2opO-l_e2&sig=7WkwQykEY5uH15J6cSrftqDcxZY&hl=en&sa=X&ei=Wm2PUvzZIq3xiAfsoYDACw&ved=0CHIQ6AEwCA#v=onepage&q=Opioid%22ultra%20low%20dose%20naltrexone%22&f=falsehttp://books.google.com.au/books?id=zqj2vy6VFUcC&pg=PA9&lpg=PA9&dq=Opioid%22ultra+low+dose+naltrexone%22&source=bl&ots=z2opO-l_e2&sig=7WkwQykEY5uH15J6cSrftqDcxZY&hl=en&sa=X&ei=Wm2PUvzZIq3xiAfsoYDACw&ved=0CHIQ6AEwCA#v=onepage&q=Opioid%22ultra%20low%20dose%20naltrexone%22&f=falsehttp://books.google.com.au/books?id=JG64gRbV3DYC&pg=PA28&lpg=PA28&dq=:+A+Novel+Analgesic+that+Binds+Filamin+A+to+Control+Opioid+Signaling&source=bl&ots=5Vj2XBc6s3&sig=DNyQxUHFauxDTtD6F1lApullUGM&hl=en&sa=X&ei=0qCfUueNNeayiQfe2ID4DA&ved=0CEoQ6AEwAw#v=onepage&q=%3A%20A%20Novel%20Analgesic%20that%20Binds%20Filamin%20A%20to%20Control%20Opioid%20Signaling&f=falsehttp://books.google.com.au/books?id=JG64gRbV3DYC&pg=PA28&lpg=PA28&dq=:+A+Novel+Analgesic+that+Binds+Filamin+A+to+Control+Opioid+Signaling&source=bl&ots=5Vj2XBc6s3&sig=DNyQxUHFauxDTtD6F1lApullUGM&hl=en&sa=X&ei=0qCfUueNNeayiQfe2ID4DA&ved=0CEoQ6AEwAw#v=onepage&q=%3A%20A%20Novel%20Analgesic%20that%20Binds%20Filamin%20A%20to%20Control%20Opioid%20Signaling&f=falsehttp://books.google.com.au/books?id=JG64gRbV3DYC&pg=PA28&lpg=PA28&dq=:+A+Novel+Analgesic+that+Binds+Filamin+A+to+Control+Opioid+Signaling&source=bl&ots=5Vj2XBc6s3&sig=DNyQxUHFauxDTtD6F1lApullUGM&hl=en&sa=X&ei=0qCfUueNNeayiQfe2ID4DA&ved=0CEoQ6AEwAw#v=onepage&q=%3A%20A%20Novel%20Analgesic%20that%20Binds%20Filamin%20A%20to%20Control%20Opioid%20Signaling&f=falsehttp://books.google.com.au/books?id=JG64gRbV3DYC&pg=PA28&lpg=PA28&dq=:+A+Novel+Analgesic+that+Binds+Filamin+A+to+Control+Opioid+Signaling&source=bl&ots=5Vj2XBc6s3&sig=DNyQxUHFauxDTtD6F1lApullUGM&hl=en&sa=X&ei=0qCfUueNNeayiQfe2ID4DA&ved=0CEoQ6AEwAw#v=onepage&q=%3A%20A%20Novel%20Analgesic%20that%20Binds%20Filamin%20A%20to%20Control%20Opioid%20Signaling&f=falsehttp://books.google.com.au/books?id=JG64gRbV3DYC&pg=PA28&lpg=PA28&dq=:+A+Novel+Analgesic+that+Binds+Filamin+A+to+Control+Opioid+Signaling&source=bl&ots=5Vj2XBc6s3&sig=DNyQxUHFauxDTtD6F1lApullUGM&hl=en&sa=X&ei=0qCfUueNNeayiQfe2ID4DA&ved=0CEoQ6AEwAw#v=onepage&q=%3A%20A%20Novel%20Analgesic%20that%20Binds%20Filamin%20A%20to%20Control%20Opioid%20Signaling&f=falsehttp://books.google.com.au/books?id=JG64gRbV3DYC&pg=PA28&lpg=PA28&dq=:+A+Novel+Analgesic+that+Binds+Filamin+A+to+Control+Opioid+Signaling&source=bl&ots=5Vj2XBc6s3&sig=DNyQxUHFauxDTtD6F1lApullUGM&hl=en&sa=X&ei=0qCfUueNNeayiQfe2ID4DA&ved=0CEoQ6AEwAw#v=onepage&q=%3A%20A%20Novel%20Analgesic%20that%20Binds%20Filamin%20A%20to%20Control%20Opioid%20Signaling&f=falsehttp://books.google.com.au/books?id=JG64gRbV3DYC&pg=PA28&lpg=PA28&dq=:+A+Novel+Analgesic+that+Binds+Filamin+A+to+Control+Opioid+Signaling&source=bl&ots=5Vj2XBc6s3&sig=DNyQxUHFauxDTtD6F1lApullUGM&hl=en&sa=X&ei=0qCfUueNNeayiQfe2ID4DA&ved=0CEoQ6AEwAw#v=onepage&q=%3A%20A%20Novel%20Analgesic%20that%20Binds%20Filamin%20A%20to%20Control%20Opioid%20Signaling&f=falsehttp://books.google.com.au/books?id=JG64gRbV3DYC&pg=PA28&lpg=PA28&dq=:+A+Novel+Analgesic+that+Binds+Filamin+A+to+Control+Opioid+Signaling&source=bl&ots=5Vj2XBc6s3&sig=DNyQxUHFauxDTtD6F1lApullUGM&hl=en&sa=X&ei=0qCfUueNNeayiQfe2ID4DA&ved=0CEoQ6AEwAw#v=onepage&q=%3A%20A%20Novel%20Analgesic%20that%20Binds%20Filamin%20A%20to%20Control%20Opioid%20Signaling&f=falsehttp://books.google.com.au/books?id=JG64gRbV3DYC&pg=PA28&lpg=PA28&dq=:+A+Novel+Analgesic+that+Binds+Filamin+A+to+Control+Opioid+Signaling&source=bl&ots=5Vj2XBc6s3&sig=DNyQxUHFauxDTtD6F1lApullUGM&hl=en&sa=X&ei=0qCfUueNNeayiQfe2ID4DA&ved=0CEoQ6AEwAw#v=onepage&q=%3A%20A%20Novel%20Analgesic%20that%20Binds%20Filamin%20A%20to%20Control%20Opioid%20Signaling&f=falsehttp://books.google.com.au/books?id=zqj2vy6VFUcC&pg=PA9&lpg=PA9&dq=Opioid%22ultra+low+dose+naltrexone%22&source=bl&ots=z2opO-l_e2&sig=7WkwQykEY5uH15J6cSrftqDcxZY&hl=en&sa=X&ei=Wm2PUvzZIq3xiAfsoYDACw&ved=0CHIQ6AEwCA#v=onepage&q=Opioid%22ultra%20low%20dose%20naltrexone%22&f=falsehttp://books.google.com.au/books?id=zqj2vy6VFUcC&pg=PA9&lpg=PA9&dq=Opioid%22ultra+low+dose+naltrexone%22&source=bl&ots=z2opO-l_e2&sig=7WkwQykEY5uH15J6cSrftqDcxZY&hl=en&sa=X&ei=Wm2PUvzZIq3xiAfsoYDACw&ved=0CHIQ6AEwCA#v=onepage&q=Opioid%22ultra%20low%20dose%20naltrexone%22&f=falsehttp://books.google.com.au/books?id=zqj2vy6VFUcC&pg=PA9&lpg=PA9&dq=Opioid%22ultra+low+dose+naltrexone%22&source=bl&ots=z2opO-l_e2&sig=7WkwQykEY5uH15J6cSrftqDcxZY&hl=en&sa=X&ei=Wm2PUvzZIq3xiAfsoYDACw&ved=0CHIQ6AEwCA#v=onepage&q=Opioid%22ultra%20low%20dose%20naltrexone%22&f=falsehttp://books.google.com.au/books?id=zqj2vy6VFUcC&pg=PA9&lpg=PA9&dq=Opioid%22ultra+low+dose+naltrexone%22&source=bl&ots=z2opO-l_e2&sig=7WkwQykEY5uH15J6cSrftqDcxZY&hl=en&sa=X&ei=Wm2PUvzZIq3xiAfsoYDACw&ved=0CHIQ6AEwCA#v=onepage&q=Opioid%22ultra%20low%20dose%20naltrexone%22&f=falsehttp://www.paintrials.com/publications/pti609_JournalArticle.pdf


25/50


Why so much excitement about LDN if my doctor doesn't know about it?

LDN

"Easily compoundable at local pharmacies LDN will never get financial support from

drug companies for drug trials but studies are being done. (The FM trials, below,

were sponsored by the American Fibromyalgia Association.) In 2013, 23 LDN trials

(underway or completed) on disorders ranging from fibromyalgia to alcoholism abuse

to multiple sclerosis to narcotics withdrawal ...."http://www.cortjohnson.org/blog/2013/08/28/mecfs-doc-asserts-low-dose-naltrexone-becoming-

standard-treatment-chronic-fatigue-syndrome-fibromyalgia/

Read more: Low Dose Naltrexone Becoming Standard Treatment for Chronic

Fatigue Syndrome and Fibromyalgia http://www.cortjohnson.org/blog/2013/08/28/mecfs-doc-asserts-low-dose-naltrexone-becoming-standard-treatment-chronic-fatigue-syndrome-

fibromyalgia/

De Meirleir begins this latest video talk by referring to the exciting but small

LDN/Fibromyalgia study at Stanford. (Stanfords 2009study found that LDN

significantly reduced pain, fatigue, and stress, and helped to improve sleep and

reduce gut issues and headaches.

De Meirleir explained that LDN is an opiate receptor blocker and is used in very

small doses (0.5-5.5 mg/day) relative to its normal dosing (5 grams, which is 5000

mg). It turns out that the partial blockage of the opioid receptors tricks the brain into

producing more of its own opiates, thus reducing pain and improving sleep (but not

generally reducing fatigue).

Read more: Low Dose Naltrexone Becoming Standard Treatment for Chronic

Fatigue Syndrome and Fibromyalgia more athttp://www.cortjohnson.org/blog/2013/08/28/mecfs-doc-asserts-low-dose-naltrexone-becoming-

standard-treatment-chronic-fatigue-syndrome-fibromyalgia/

I want to make a plug for Low Dose Naltrexone Dr. Nancy KlimasSimmaronRoundtable Meeting: Read more: Low Dose Naltrexone Becoming StandardTreatment for Chronic Fatigue Syndrome and Fibromyalgiahttp://www.cortjohnson.org/blog/2013/08/28/mecfs-doc-asserts-low-dose-naltrexone-becoming-standard-treatment-chronic-fatigue-syndrome-fibromyalgia/

See more atThe Doctor's Medical Library : Low Dose Naltrexone by Ron Kennedy M.D.http://www.medical-library.net/content/view/533/41/

http://www.cortjohnson.org/treating-chronic-fatigue-syndrome-mecfs/drugs-for-chronic-fatigue-syndrome-mecfs-treatment/low-dose-naltrexone-ldn-fibromyalgia-chronic-fatigue-syndrom/

http://www.cortjohnson.org/blog/2013/08/28/mecfs-doc-asserts-low-dose-naltrexone-becoming-standard-treatment-chronic-fatigue-syndrome-fibromyalgia/http://www.cortjohnson.org/blog/2013/08/28/mecfs-doc-asserts-low-dose-naltrexone-becoming-standard-treatment-chronic-fatigue-syndrome-fibromyalgia/http://www.cortjohnson.org/blog/2013/08/28/mecfs-doc-asserts-low-dose-naltrexone-becoming-standard-treatment-chronic-fatigue-syndrome-fibromyalgia/http://www.cortjohnson.org/blog/2013/08/28/mecfs-doc-asserts-low-dose-naltrexone-becoming-standard-treatment-chronic-fatigue-syndrome-fibromyalgia/http://www.cortjohnson.org/blog/2013/08/28/mecfs-doc-asserts-low-dose-naltrexone-becoming-standard-treatment-chronic-fatigue-syndrome-fibromyalgia/http://www.cortjohnson.org/blog/2013/08/28/mecfs-doc-asserts-low-dose-naltrexone-becoming-standard-treatment-chronic-fatigue-syndrome-fibromyalgia/http://www.cortjohnson.org/blog/2013/08/28/mecfs-doc-asserts-low-dose-naltrexone-becoming-standard-treatment-chronic-fatigue-syndrome-fibromyalgia/http://www.cortjohnson.org/blog/2013/08/28/mecfs-doc-asserts-low-dose-naltrexone-becoming-standard-treatment-chronic-fatigue-syndrome-fibromyalgia/http://www.cortjohnson.org/blog/2013/08/28/mecfs-doc-asserts-low-dose-naltrexone-becoming-standard-treatment-chronic-fatigue-syndrome-fibromyalgia/http://www.cortjohnson.org/blog/2013/08/28/mecfs-doc-asserts-low-dose-naltrexone-becoming-standard-treatment-chronic-fatigue-syndrome-fibromyalgia/http://www.cortjohnson.org/blog/2013/08/28/mecfs-doc-asserts-low-dose-naltrexone-becoming-standard-treatment-chronic-fatigue-syndrome-fibromyalgia/http://www.cortjohnson.org/blog/2013/08/28/mecfs-doc-asserts-low-dose-naltrexone-becoming-standard-treatment-chronic-fatigue-syndrome-fibromyalgia/http://www.cortjohnson.org/blog/2013/08/28/mecfs-doc-asserts-low-dose-naltrexone-becoming-standard-treatment-chronic-fatigue-syndrome-fibromyalgia/http://www.medical-library.net/content/view/533/41/http://www.medical-library.net/content/view/533/41/http://www.cortjohnson.org/treating-chronic-fatigue-syndrome-mecfs/drugs-for-chronic-fatigue-syndrome-mecfs-treatment/low-dose-naltrexone-ldn-fibromyalgia-chronic-fatigue-syndrom/http://www.cortjohnson.org/treating-chronic-fatigue-syndrome-mecfs/drugs-for-chronic-fatigue-syndrome-mecfs-treatment/low-dose-naltrexone-ldn-fibromyalgia-chronic-fatigue-syndrom/http://www.cortjohnson.org/treating-chronic-fatigue-syndrome-mecfs/drugs-for-chronic-fatigue-syndrome-mecfs-treatment/low-dose-naltrexone-ldn-fibromyalgia-chronic-fatigue-syndrom/http://www.cortjohnson.org/treating-chronic-fatigue-syndrome-mecfs/drugs-for-chronic-fatigue-syndrome-mecfs-treatment/low-dose-naltrexone-ldn-fibromyalgia-chronic-fatigue-syndrom/http://pain-topics.org/pdf/OpioidAntagonistsForPain.pdfhttp://pain-topics.org/pdf/OpioidAntagonistsForPain.pdfhttp://pain-topics.org/pdf/OpioidAntagonistsForPain.pdfhttp://www.cortjohnson.org/treating-chronic-fatigue-syndrome-mecfs/drugs-for-chronic-fatigue-syndrome-mecfs-treatment/low-dose-naltrexone-ldn-fibromyalgia-chronic-fatigue-syndrom/http://www.cortjohnson.org/treating-chronic-fatigue-syndrome-mecfs/drugs-for-chronic-fatigue-syndrome-mecfs-treatment/low-dose-naltrexone-ldn-fibromyalgia-chronic-fatigue-syndrom/http://www.cortjohnson.org/treating-chronic-fatigue-syndrome-mecfs/drugs-for-chronic-fatigue-syndrome-mecfs-treatment/low-dose-naltrexone-ldn-fibromyalgia-chronic-fatigue-syndrom/http://www.medical-library.net/content/view/533/41/http://www.cortjohnson.org/blog/2013/08/28/mecfs-doc-asserts-low-dose-naltrexone-becoming-standard-treatment-chronic-fatigue-syndrome-fibromyalgia/http://www.cortjohnson.org/blog/2013/08/28/mecfs-doc-asserts-low-dose-naltrexone-becoming-standard-treatment-chronic-fatigue-syndrome-fibromyalgia/http://www.cortjohnson.org/blog/2013/08/28/mecfs-doc-asserts-low-dose-naltrexone-becoming-standard-treatment-chronic-fatigue-syndrome-fibromyalgia/http://www.cortjohnson.org/blog/2013/08/28/mecfs-doc-asserts-low-dose-naltrexone-becoming-standard-treatment-chronic-fatigue-syndrome-fibromyalgia/http://www.cortjohnson.org/blog/2013/08/28/mecfs-doc-asserts-low-dose-naltrexone-becoming-standard-treatment-chronic-fatigue-syndrome-fibromyalgia/http://www.cortjohnson.org/blog/2013/08/28/mecfs-doc-asserts-low-dose-naltrexone-becoming-standard-treatment-chronic-fatigue-syndrome-fibromyalgia/http://www.cortjohnson.org/blog/2013/08/28/mecfs-doc-asserts-low-dose-naltrexone-becoming-standard-treatment-chronic-fatigue-syndrome-fibromyalgia/http://www.cortjohnson.org/blog/2013/08/28/mecfs-doc-asserts-low-dose-naltrexone-becoming-standard-treatment-chronic-fatigue-syndrome-fibromyalgia/http://www.cortjohnson.org/blog/2013/08/28/mecfs-doc-asserts-low-dose-naltrexone-becoming-standard-treatment-chronic-fatigue-syndrome-fibromyalgia/


26/50


More books are being published like this one below - see the description for more

information about the history and uses of LDN

The Promise Of Low Dose Naltrexone Therapy: Potential

Benefits in Cancer, Autoimmune, Neurological and Infectious

Disorders [Paperback]

Elaine A. Moore(Author),Dr. Yash P.

Agrawal(Foreword),Samantha Wilkinson(Collaborator)

http://www.amazon.com/Promise-Low-Dose-Naltrexone-Therapy/dp/0786437154/ref=sr_1_1?s=books&ie=UTF8&qid=1360756230

&sr=1-1&keywords=low+dose+naltrexone

Publication Date: December 1, 2008| ISBN-

10:0786437154 | ISBN-13:978-0786437153

Naltrexone is an opiate antagonist drug developed in

the 1970s and approved by the FDA in 1984 for opiate

and drug abuse treatment. When used at much lower

doses in an off-label protocol referred to as low dose

naltrexone (LDN), the drug has been shown to halt

disease progression in Crohn's disease and certain

cancers, to reduce symptoms in multiple sclerosis and

autism, and to improve numerous autoimmune and

neurodegenerative conditions, including Parkinson's

disease and amyotrophic lateral sclerosis (ALS).

Grounded in clinical and scientific research, this book

describes the history of naltrexone, its potential

therapeutic uses, its effects on the immune system, itspharmacological properties, and how the drug is

administered. It also lists fillers and compounding

pharmacies, doctors who prescribe LDN, and patient

resources, and includes interviews with LDN patients

and researchers.
http://www.amazon.com/Elaine-A.-Moore/e/B001JRZ6RA/ref=ntt_athr_dp_pel_1http://www.amazon.com/Elaine-A.-Moore/e/B001JRZ6RA/ref=ntt_athr_dp_pel_1http://www.amazon.com/s/ref=ntt_athr_dp_sr_2?_encoding=UTF8&field-author=Dr.%20Yash%20P.%20Agrawal&search-alias=books&sort=relevancerankhttp://www.amazon.com/s/ref=ntt_athr_dp_sr_2?_encoding=UTF8&field-author=Dr.%20Yash%20P.%20Agrawal&search-alias=books&sort=relevancerankhttp://www.amazon.com/s/ref=ntt_athr_dp_sr_2?_encoding=UTF8&field-author=Dr.%20Yash%20P.%20Agrawal&search-alias=books&sort=relevancerankhttp://www.amazon.com/s/ref=ntt_athr_dp_sr_2?_encoding=UTF8&field-author=Dr.%20Yash%20P.%20Agrawal&search-alias=books&sort=relevancerankhttp://www.amazon.com/s/ref=ntt_athr_dp_sr_3?_encoding=UTF8&field-author=Samantha%20Wilkinson&search-alias=books&sort=relevancerankhttp://www.amazon.com/s/ref=ntt_athr_dp_sr_3?_encoding=UTF8&field-author=Samantha%20Wilkinson&search-alias=books&sort=relevancerankhttp://www.amazon.com/s/ref=ntt_athr_dp_sr_3?_encoding=UTF8&field-author=Samantha%20Wilkinson&search-alias=books&sort=relevancerankhttp://www.amazon.com/Promise-Low-Dose-Naltrexone-Therapy/dp/0786437154/ref=sr_1_1?s=books&ie=UTF8&qid=1360756230&sr=1-1&keywords=low+dose+naltrexonehttp://www.amazon.com/Promise-Low-Dose-Naltrexone-Therapy/dp/0786437154/ref=sr_1_1?s=books&ie=UTF8&qid=1360756230&sr=1-1&keywords=low+dose+naltrexonehttp://www.amazon.com/Promise-Low-Dose-Naltrexone-Therapy/dp/0786437154/ref=sr_1_1?s=books&ie=UTF8&qid=1360756230&sr=1-1&keywords=low+dose+naltrexonehttp://www.amazon.com/Promise-Low-Dose-Naltrexone-Therapy/dp/0786437154/ref=sr_1_1?s=books&ie=UTF8&qid=1360756230&sr=1-1&keywords=low+dose+naltrexonehttp://www.amazon.com/Promise-Low-Dose-Naltrexone-Therapy/dp/0786437154/ref=sr_1_1?s=books&ie=UTF8&qid=1360756230&sr=1-1&keywords=low+dose+naltrexonehttp://www.amazon.com/Promise-Low-Dose-Naltrexone-Therapy/dp/0786437154/ref=sr_1_1?s=books&ie=UTF8&qid=1360756230&sr=1-1&keywords=low+dose+naltrexonehttp://www.amazon.com/Promise-Low-Dose-Naltrexone-Therapy/dp/0786437154/ref=sr_1_1?s=books&ie=UTF8&qid=1360756230&sr=1-1&keywords=low+dose+naltrexonehttp://www.amazon.com/s/ref=ntt_athr_dp_sr_3?_encoding=UTF8&field-author=Samantha%20Wilkinson&search-alias=books&sort=relevancerankhttp://www.amazon.com/s/ref=ntt_athr_dp_sr_2?_encoding=UTF8&field-author=Dr.%20Yash%20P.%20Agrawal&search-alias=books&sort=relevancerankhttp://www.amazon.com/s/ref=ntt_athr_dp_sr_2?_encoding=UTF8&field-author=Dr.%20Yash%20P.%20Agrawal&search-alias=books&sort=relevancerankhttp://www.amazon.com/Elaine-A.-Moore/e/B001JRZ6RA/ref=ntt_athr_dp_pel_1


27/50


Oxytrex Studies highlight need for inverse titration of

doses.

The study and patent of a combination drug called

"Oxytrex" (Oxycontin plus Ultra-low dose Naltrexone)

as single medication has made some progress intothis area of combining ultra low dose natrexone with

opioid use. It also has application as an abuse

resistant prescription medication.

see p.4. of Pharma Note Jan 2013

http://copnt13.cop.ufl.edu/doty/pep/pharmanote/January2013.pdf

There is enthusiasm for a combination medication suchas Oxytrex based on both the abuse resistant concernsas well as the opioid tolerance prevention. FDAapproval of Oxytrex is still undetermined.

The Oxytrex concept has exciting possibilities in theapplication of managing pain and reducing opioidtolerance if the medication were to be available.

However for those seeking to reduce opioid medicationand move onto LDN taking ULDN and opioid doses asindividual medications and titrating the doses inverselyallows for a dose by dose tailoring of each medication.

see alsohttp://opioids.com/tolerance/oxytrex.htm

and

Journal : Clinical Medicine Insights: Therapeutics

Ultra-Low-Dose Naloxone or Naltrexone to

Improve Opioid Analgesia: The History, the

Mystery and a Novel Approach

http://www.la-press.com/ultra-low-dose-naloxone-or-

naltrexone-to-improve-opioid-analgesia-the--article-

a2351

Clinical MedicineInsights: TherapeuticsR e v i ewClinical Medicine Insights: Therapeutics

2010:2 857Ultra-Low-Dose Naloxone or

Naltrexone to ImproveOpioid Analgesia: The

History, the Mystery and a

Novel Approach

Lindsay H. Burns1 and Hoau-YanWang21Pain Therapeutics Inc., San Mateo, CA,USA. 2Deparment of Pharmacology andPhysiology, CUNY Medical School,

Abstract: Combining opioid

agonists with ultra-low (typically pg-ng/kg) doses of the opioid

antagonists naloxone or naltrexone

can enhance analgesic efficacy and

decrease certain side effects. Such

combinations have also been shown

to decrease tolerance, dependence

and addictive potential in animals.

We now know that ultra-low-dose

naloxone/naltrexone effects occur by

preventing a G protein coupling

switch (Gi/o to Gs) of the mu opioidreceptor (MOR) that occurs briefly

after acute administration or

persistently after chronic

administration of opioids. The

picomolar binding site for naloxone

or naltrexone in these effects is on

the scaffolding protein filamin A

(FLNA), rather than on opioid

receptors. Interestingly, a second,

nanomolar binding site on FLNA

may disrupt the benefits of binding

the picomolar site, perhapsexplaining why ultra-low-dose

naloxone/naltrexone effects vanish at

just slightly higher doses. A novel

analgesic drug candidate aims to

avoid this issue by binding only the

high-affinity FLNA site, while

simultaneously activating MOR.

Binding this single site on FLNA

also provides anti-inflammatory

activity.Keywords: signaling, filamin A,

naloxone, naltrexone, conditioned placepreference, anti-inflammatory
http://copnt13.cop.ufl.edu/doty/pep/pharmanote/January2013.pdfhttp://copnt13.cop.ufl.edu/doty/pep/pharmanote/January2013.pdfhttp://opioids.com/tolerance/oxytrex.htmhttp://opioids.com/tolerance/oxytrex.htmhttp://www.la-press.com/ultra-low-dose-naloxone-or-naltrexone-to-improve-opioid-analgesia-the--article-a2351http://www.la-press.com/ultra-low-dose-naloxone-or-naltrexone-to-improve-opioid-analgesia-the--article-a2351http://www.la-press.com/ultra-low-dose-naloxone-or-naltrexone-to-improve-opioid-analgesia-the--article-a2351http://www.la-press.com/ultra-low-dose-naloxone-or-naltrexone-to-improve-opioid-analgesia-the--article-a2351http://www.la-press.com/ultra-low-dose-naloxone-or-naltrexone-to-improve-opioid-analgesia-the--article-a2351http://www.la-press.com/ultra-low-dose-naloxone-or-naltrexone-to-improve-opioid-analgesia-the--article-a2351http://www.la-press.com/ultra-low-dose-naloxone-or-naltrexone-to-improve-opioid-analgesia-the--article-a2351http://opioids.com/tolerance/oxytrex.htmhttp://copnt13.cop.ufl.edu/doty/pep/pharmanote/January2013.pdf


28/50


An Extract from "High-Affinity Naloxone Binding to Filamin A Prevents Mu Opioid

ReceptorGs Coupling Underlying Opioid Tolerance and Dependence"

...." Ultra-low-dose opioid antagonists have been shown to enhance opioid

analgesia and attenuate tolerance and dependence, with a mechanism long

hypothesized as a blockade of excitatory signaling opioid receptors[1][4].Ultra-

low-dose opioid antagonists can also reverse hyperalgesia caused by acute, low-

dose opioids to produce analgesia[5].Additionally, ultra-low-dose naltrexone has

recently been shown to attenuate opioid reward or addictive properties ...."

..."....... This high-affinity binding site in c-terminal FLNA therefore appears to

underlie the paradoxical enhancement of opioid analgesia and prevention of

analgesic tolerance and dependence by ultra-low-dose opioid antagonists. Inidentifying the binding site though which ultra-low-dose opioid antagonists prevent

MORGs coupling, our data also reveal an important regulation of MORG protein

coupling by filamin A...."

Source:

http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0001554

More information about the studies and development of Oxytrex

Oxycodone Plus Ultra-Low-Dose Naltrexone Attenuates Neuropathic Pain and

Associated -Opioid ReceptorGsCoupling

Tally M. Largent-Milnes, Wenhong Guo, Hoau-Yan Wang, Lindsay H. Burns, Todd W. Vanderah

Received 14 August 2007; received in revised form 4 February 2008; accepted 7March 2008. published online 12 May 2008.seehttp://www.jpain.org/article/S1526-5900(08)00480-X/abstract

see alsohttp://www.researchgate.net/publication/226837972_Ultra-Low-Dose_Opioid_Antagonists_Enhance_Opioid_Analgesia_and_Reduce_Tolerance

Pharma Note newsletter Vol 28 Issue 4 Jan 2013discusses the various combinationmedications, their developments effects, doses and uses.

pp 1-2 Pharmacology of narcotics (opioids)Pp. 2 and 4 Mechanisms of Abuse resistance and deterrence & opioid receptoreffects p 3 list of FDA approved combination opioid and abuse deterrentcombination medications.p. 4 Novel abuse resistent narcotics under review - includes Oxytrex and safetyof oral combination doses of opioid medications with naloxone and naltrexonecombinations.

See http://copnt13.cop.ufl.edu/doty/pep/pharmanote/January2013.pdf
http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0001554#pone.0001554-Crain1http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0001554#pone.0001554-Crain1http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0001554#pone.0001554-Wang1http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0001554#pone.0001554-Wang1http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0001554#pone.0001554-Crain3http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0001554#pone.0001554-Crain3http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0001554#pone.0001554-Crain3http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0001554http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0001554http://www.jpain.org/article/S1526-5900(08)00480-X/abstracthttp://www.jpain.org/article/S1526-5900(08)00480-X/abstracthttp://www.jpain.org/article/S1526-5900(08)00480-X/abstracthttp://www.jpain.org/article/S1526-5900(08)00480-X/abstracthttp://www.jpain.org/article/S1526-5900(08)00480-X/abstracthttp://www.jpain.org/article/S1526-5900(08)00480-X/abstracthttp://www.jpain.org/article/S1526-5900(08)00480-X/abstracthttp://www.jpain.org/article/S1526-5900(08)00480-X/abstracthttp://www.jpain.org/article/S1526-5900(08)00480-X/abstracthttp://www.jpain.org/article/S1526-5900(08)00480-X/abstracthttp://www.jpain.org/article/S1526-5900(08)00480-X/abstracthttp://www.jpain.org/article/S1526-5900(08)00480-X/abstracthttp://www.researchgate.net/publication/226837972_Ultra-Low-Dose_Opioid_Antagonists_Enhance_Opioid_Analgesia_and_Reduce_Tolerancehttp://www.researchgate.net/publication/226837972_Ultra-Low-Dose_Opioid_Antagonists_Enhance_Opioid_Analgesia_and_Reduce_Tolerancehttp://www.researchgate.net/publication/226837972_Ultra-Low-Dose_Opioid_Antagonists_Enhance_Opioid_Analgesia_and_Reduce_Tolerancehttp://www.researchgate.net/publication/226837972_Ultra-Low-Dose_Opioid_Antagonists_Enhance_Opioid_Analgesia_and_Reduce_Tolerancehttp://copnt13.cop.ufl.edu/doty/pep/pharmanote/January2013.pdfhttp://copnt13.cop.ufl.edu/doty/pep/pharmanote/January2013.pdfmailto:[email protected]://copnt13.cop.ufl.edu/doty/pep/pharmanote/January2013.pdfhttp://www.researchgate.net/publication/226837972_Ultra-Low-Dose_Opioid_Antagonists_Enhance_Opioid_Analgesia_and_Reduce_Tolerancehttp://www.researchgate.net/publication/226837972_Ultra-Low-Dose_Opioid_Antagonists_Enhance_Opioid_Analgesia_and_Reduce_Tolerancehttp://www.jpain.org/article/S1526-5900(08)00480-X/abstracthttp://www.jpain.org/article/S1526-5900(08)00480-X/abstracthttp://www.jpain.org/article/S1526-5900(08)00480-X/abstracthttp://www.jpain.org/article/S1526-5900(08)00480-X/abstracthttp://www.jpain.org/article/S1526-5900(08)00480-X/abstracthttp://www.jpain.org/article/S1526-5900(08)00480-X/abstracthttp://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0001554http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0001554#pone.0001554-Crain3http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0001554#pone.0001554-Wang1http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0001554#pone.0001554-Crain1


29/50


Studied, Recommended, Prescribed & Advocated by...

The following list of some of the Professors, doctors and researchers who have

published studies, peer review articles and online discussions of ULDN and LDN. It

is by no means an exhaustive list but is indicative of the expertise and experience of

those professionals advocating on behalf of the well being of patients that this cheap,

safe and effective medication be seriously considered and tried.

This list includes;

Dr Sean Mackey, MD, PhDRedlich Professor, Stanford Division of Pain MedicinePresident-elect, American Academy of Pain MedicineAssistant professor of anaesthesia at the Stanford University Medical Center

Research Channel update on Fibromyalgia and pain treatments

see

https://www.youtube.com/watch?v=jtc2JARVpPw

Video Uploaded to You Tube on 1 May 2009

Fibromyalgia is a mysterious disorder of unknown cause characterized by widespread

pain, abnormal pain processing, sleep disturbance, fatigue and often psychological

distress. According to the CDC, fibromyalgia affects an estimated 5 million adults. Dr.

Sean Mackey, assistant professor of anesthesia at the Stanford University MedicalCenter, discusses our current understanding of this cryptic disorder: its pathology,

diagnosis and treatment.

@36 - 39 minutes Dr Mackey discusses long term use of opiates.. can cause more pain than less..

healthy people feel good after working out.. fibro patients feel worse

@ 42 minutes discusses LDN

Source:https://www.youtube.com/watch?v=jtc2JARVpPw

Stanford School of Medicine - Systems Neuroscience and Pain LabFibromyalgia Symptoms are reduced by low-dose naltrexone: A pilot study.Pain Medicine (2009)Jarred W. Younger and Sean C. Mackeyhttp://med.stanford.edu/snapl/research/ldn.html

see alsohttp://www.painmattersfilm.com/
https://www.youtube.com/watch?v=jtc2JARVpPwhttps://www.youtube.com/watch?v=jtc2JARVpPwhttps://www.youtube.com/watch?v=jtc2JARVpPwhttps://www.youtube.com/watch?v=jtc2JARVpPwhttps://www.youtube.com/watch?v=jtc2JARVpPwhttp://med.stanford.edu/snapl/research/ldn.htmlhttp://med.stanford.edu/snapl/research/ldn.htmlhttp://www.painmattersfilm.com/http://www.painmattersfilm.com/http://www.painmattersfilm.com/http://www.painmattersfilm.com/http://med.stanford.edu/snapl/research/ldn.htmlhttps://www.youtube.com/watch?v=jtc2JARVpPwhttps://www.youtube.com/watch?v=jtc2JARVpPw


30/50


Catherine Cahill, PhD

University of California

Associate Professor

http://www.anesthesiology.uci.edu/index.shtml

http://www.anesthesiology.uci.edu/research_faculty_cahill.shtml

Dr. Tom GilhoolyMBChB MRCGP (Glasgow)One of the keynote speakers and author of many articles for the LDN Research

Trust Dr Tom G talks about LDN at world conference

Dr Tom Gilhooly is a 46-year-old General Practitioner who has worked in the East End of

Glasgow for the past 16 years. He is a nationally-recognised expert on addiction, and

advises both the Scottish Parliament and the UK Government on drug strategy.

Tom is married with three children, and he also has two dogs.

He has a long-term interest in nutrition, and founded The Centre for Nutritional Studies

(CNS) Ltd in 2002, with the aim of carrying out nutritional research. In the past two years

he has become aware of LDN, and is an enthusiastic supporter of this treatment (as well

as natural treatments) for MS. He now runs an MS clinic in Glasgow.

http://www.ldnresearchtrust.org/node/3

http://www.youtube.com/watch?v=fWrG_UQtbsU

eg See page 3 of:

http://www.ldnresearchtrustfiles.co.uk/docs/May%20-%20Newsletter.pdf

andhttp://www.skipspharmacy.com/wplog/pharmacy-news/ldn-2008-videos-here/
http://www.anesthesiology.uci.edu/index.shtmlhttp://www.anesthesiology.uci.edu/index.shtmlhttp://www.anesthesiology.uci.edu/research_faculty_cahill.shtmlhttp://www.anesthesiology.uci.edu/research_faculty_cahill.shtmlhttp://www.ldnresearchtrust.org/node/3http://www.ldnresearchtrust.org/node/3http://www.youtube.com/watch?v=fWrG_UQtbsUhttp://www.youtube.com/watch?v=fWrG_UQtbsUhttp://www.ldnresearchtrustfiles.co.uk/docs/May%20-%20Newsletter.pdfhttp://www.ldnresearchtrustfiles.co.uk/docs/May%20-%20Newsletter.pdfhttp://www.skipspharmacy.com/wplog/pharmacy-news/ldn-2008-videos-here/http://www.skipspharmacy.com/wplog/pharmacy-news/ldn-2008-videos-here/http://www.skipspharmacy.com/wplog/pharmacy-news/ldn-2008-videos-here/http://www.ldnresearchtrustfiles.co.uk/docs/May%20-%20Newsletter.pdfhttp://www.youtube.com/watch?v=fWrG_UQtbsUhttp://www.ldnresearchtrust.org/node/3http://www.anesthesiology.uci.edu/research_faculty_cahill.shtmlhttp://www.anesthesiology.uci.edu/index.shtml


31/50


Dr. Tim Gerstmar

https://www.facebook.com/AspireNaturalHealth/posts/10151779725083469

Aspire Natural Health 704 like this.

10 August at 15:00

We are experts at treat ing:

G - Can ultra-low dose naltrexone remove some of the side effects of opioidpainkillers? In the comments section of the same post, George Hendersonand Peter D (a vet anesthesiologist) discuss some preliminary research abouthow ultra-low dose naltrexone (a fraction of LDN) can be given alo

uldn inverse titration protocol final

Documents